Mycrodose Therapeutics

US-Based Pharmaceutical company specializing in the advanced drug delivery of active pharmaceutical ingredients.

Add To Watchlist
General Information
Company Name
Mycrodose Therapeutics
Founded Year
2020
Location (Offices)
San Diego, United States +1
Founders / Decision Makers
Chad Conner - Chief Executive Officer
Number of Employees
4
Industries
Health Care, Pharmaceutical
Funding Stage
Seed
Social Media

Mycrodose Therapeutics - Company Profile

Mycrodose Therapeutics is a U.S.-based pharmaceutical company headquartered in San Diego, California. It specializes in the advanced drug delivery of active pharmaceutical ingredients, particularly DEA Schedule I & III drugs and other compounds to treat cancer-related conditions, mental health, and cognitive degenerative diseases. Founded in 2020, the company operates a California laboratory with a transdermal department equipped with full in-vitro and analytical capacities, ensuring that all intellectual property and proprietary data remains in-house.

Mycrodose Therapeutics touts its IP-Protected Sustained Microdosing Technology™ as a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages. This technology also sets the stage for an expandable and scalable business model within the health care and pharmaceutical industries.

The company recently received a Seed Round investment on 21 September 2021 from a diverse group of investors, including Empath Ventures, K2 & Associates, Negev Capital, Supernode, The Conscious Fund, Ambria Capital, LLC, Joe Thomas, Receptor, and Vinay Hiremath.

Taxonomy: pharmaceutical company, drug delivery systems, DEA Schedule I & III drugs, cancer treatment, mental health treatment, cognitive degenerative diseases treatment, transdermal delivery system, psilocybin, ketamine, intellectual property, sustainable microdosing technology, innovation, IP protection, scalable business model

Funding Rounds & Investors of Mycrodose Therapeutics (1)

View All
Funding Stage Amount No. Investors Investors Date
Seed Round Unknown 9
Empath Ventures, investor in Mycrodose Therapeutics's Seed Round round K2 & Associates, investor in Mycrodose Therapeutics's Seed Round round Negev Capital, investor in Mycrodose Therapeutics's Seed Round round Supernode, investor in Mycrodose Therapeutics's Seed Round round The Conscious Fund, investor in Mycrodose Therapeutics's Seed Round round Ambria Capital, LLC, investor in Mycrodose Therapeutics's Seed Round round
Joe Thomas, Receptor +1 		21 Sep 2021

Latest News of Mycrodose Therapeutics

View All

No recent news or press coverage available for Mycrodose Therapeutics.

Similar Companies to Mycrodose Therapeutics

View All
APS Pharmacy - Similar company to Mycrodose Therapeutics
APS Pharmacy Crafting personalized pharmaceutical solutions for improved health and wellness across a range of conditions, from hormone therapy to neurological health.
Zomanex - Similar company to Mycrodose Therapeutics
Zomanex Pioneering oral cancer treatment with innovative drug delivery technology
Vitrobio Pharma - Similar company to Mycrodose Therapeutics
Vitrobio Pharma International pharmaceutical Laboratory
Syntropharma - Similar company to Mycrodose Therapeutics
Syntropharma Creating innovative transdermal solutions from proven compounds to enhance clinical profiles and drive pharmaceutical advancement.
Neos Therapeutics, Inc. - Similar company to Mycrodose Therapeutics
Neos Therapeutics, Inc. We are creating the Specialty Pharmaceutical Company of Tomorrow...Today
Circle Decoration Circle Decoration

Want to dive deeper into Mycrodose Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now